NCT01853748 2026-02-19
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
8 trialsNCT05415215 2026-02-10
ProHer
Hoffmann-La Roche
Phase 3 Completed
NCT01494662 2026-01-23
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01975142 2025-11-24
Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Institut Curie
Phase 2 Completed
NCT05945927 2025-10-10
A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer
Hoffmann-La Roche
Completed
NCT01772472 2025-07-22
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Hoffmann-La Roche
Phase 3 Completed
NCT04509596 2025-04-01
DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer
Dizal Pharmaceuticals
Phase 1 Completed
NCT01565200 2025-03-31
ZEPHIR
Jules Bordet Institute
Phase 2 Completed